{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:05:05Z","timestamp":1787601905393,"version":"build-2736575974"},"reference-count":170,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research, New Delhi","doi-asserted-by":"publisher","award":["5\/13\/51\/2020\/NCD-III"],"award-info":[{"award-number":["5\/13\/51\/2020\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["ECR\/2016\/001863"],"award-info":[{"award-number":["ECR\/2016\/001863"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>There is a long history of informal use of Cannabis sativa (commonly called cannabis) for many purposes, including treating various ailments worldwide. However, the legalization of cannabis in multiple countries, specifically for medical purposes, has grabbed the researchers' attention to discover the scientific evidence of cannabis\u2019s beneficial effects.  Among over 500  identified compounds (cannabinoids), \u03949-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two major active cannabinoids derived from cannabis. Cannabinoids exert their effects through cannabinoid receptors (CB1R and CB2R). In the recent past, clinical trials have shown the efficacy of cannabis and cannabinoids for various human ailments such as cancer, neurological disorders, inflammatory bowel disease, chronic pain, and metabolic disorders. The commonly used constituents and derivatives of cannabis include CBD, THC, THCV, dronabinol, nabilone, and nabiximol. The cannabis constituents have also been used in combination with other agents such as megestrol acetate in some clinical trials. The common routes for the administration of cannabis are oral, sublingual, or topical. Cannabis has also been consumed through smoking, inhalation, or with food and tea. As high as 572 patients and as low as nine patients have participated in a single clinical trial. Cannabis is legalized in some countries with restrictions, such as Belize, Canada, Colombia, Costa Rica, The Czech Republic, Jamaica, Netherlands, South Africa, Spain, and Uruguay. This article provides a compilation of published studies focusing on clinal trials on the therapeutic effects of cannabis. The adverse effects of cannabis and its constituents are also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220525124818","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T05:00:21Z","timestamp":1653627621000},"page":"178-202","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Cannabis and its Constituents in Disease Management:\nInsights from Clinical Studies"],"prefix":"10.2174","volume":"30","author":[{"given":"Divya","family":"Vimal","sequence":"first","affiliation":[{"name":"Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York,\nNY, 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard Clinton","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Division of Environmental Health and Toxicology, Nitte University Centre for Science Education\nand Research (NUCSER), Nitte (Deemed to be University), Deralakatte, Mangaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Rai","sequence":"additional","affiliation":[{"name":"Department\nof Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samridhi","family":"Lal","sequence":"additional","affiliation":[{"name":"Amity Institute\nof Pharmacy, Amity University, Gurgaon, Haryana, 122413, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Environmental Health and Toxicology, Nitte University Centre for Science Education\nand Research (NUCSER), Nitte (Deemed to be University), Deralakatte, Mangaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash Chandra","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India"},{"name":"Department of Biochemistry, All India\nInstitute of Medical Sciences, Guwahati, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/138920107781387456","volume":"8","author":"Sirikantaramas S.","year":"2007","unstructured":"Sirikantaramas S.; Taura F.; Morimoto S.; Shoyama Y.; Recent advances in Cannabis sativa research: Biosynthetic studies and its potential in biotechnology. Curr Pharm Biotechnol 2007,8(4),237-243","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=2","first-page":"180","volume":"42","author":"Bridgeman M.B.","year":"2017","unstructured":"Bridgeman M.B.; Abazia D.T.; Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P 2017,42(3),180-188","journal-title":"P"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.3390\/brainsci8030040","volume":"8","author":"Cohen K.","year":"2018","unstructured":"Cohen K.; Weinstein A.; The effects of cannabinoids on executive functions: Evidence from cannabis and synthetic cannabinoids-A systematic review. Brain Sci 2018,8(3),E40","journal-title":"Brain Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1192\/bjp.bp.108.056952","volume":"196","author":"Degenhardt L.","year":"2010","unstructured":"Degenhardt L.; Coffey C.; Carlin J.B.; Swift W.; Moore E.; Patton G.C.; Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry 2010,196(4),290-295","journal-title":"Br J Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/YCO.0b013e32812144cc","volume":"20","author":"Hall W.","year":"2007","unstructured":"Hall W.; Degenhardt L.; Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 2007,20(4),393-397","journal-title":"Curr Opin Psychiatry"},{"key":"ref=6","author":"Brenneisen R.","unstructured":"Brenneisen R.;  Marijuana and the Cannabinoids, 2007, pp. 17-49"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Atakan Z.","year":"2012","unstructured":"Atakan Z.; Cannabis, a complex plant: Different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012,2(6),241-254","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"378069","DOI":"10.1155\/2014\/378069","volume":"2014","author":"Meccariello R.","year":"2014","unstructured":"Meccariello R.; Battista N.; Bradshaw H.B.; Wang H.; Endocannabinoids and reproduction. Int J Endocrinol 2014,2014,378069","journal-title":"Int J Endocrinol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13048-018-0478-9","volume":"12","author":"Walker O.S.","year":"2019","unstructured":"Walker O.S.; Holloway A.C.; Raha S.; The role of the endocannabinoid system in female reproductive tissues. J Ovarian Res 2019,12(1),3","journal-title":"J Ovarian Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0269881111405357","volume":"26","author":"Pamplona F.A.","year":"2012","unstructured":"Pamplona F.A.; Takahashi R.N.; Psychopharmacology of the endocannabinoids: Far beyond anandamide. J Psychopharmacol 2012,26(1),7-22","journal-title":"J Psychopharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"Whiting P.F.","year":"2015","unstructured":"Whiting P.F.; Wolff R.F.; Deshpande S.; Di Nisio M.; Duffy S.; Hernandez A.V.; Keurentjes J.C.; Lang S.; Misso K.; Ryder S.; Schmidlkofer S.; Westwood M.; Kleijnen J.; Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015,313(24),2456-2473","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/02791072.2013.805976","volume":"45","author":"Hazekamp A.","year":"2013","unstructured":"Hazekamp A.; Ware M.A.; Muller-Vahl K.R.; Abrams D.; Grotenhermen F.; The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs 2013,45(3),199-210","journal-title":"J Psychoactive Drugs"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4103\/jispcd.JISPCD_351_20","volume":"10","author":"Vasudevan K.","year":"2020","unstructured":"Vasudevan K.; Stahl V.; CBD-supplemented polishing powder enhances tooth polishing by inhibiting dental plaque bacteria. J Int Soc Prev Community Dent 2020,10(6),766-770","journal-title":"J Int Soc Prev Community Dent"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/molecules26020465","volume":"26","author":"Anis O.","year":"2021","unstructured":"Anis O.; Vinayaka A.C.; Shalev N.; Namdar D.; Nadarajan S.; Anil S.M.; Cohen O.; Belausov E.; Ramon J.; Mayzlish Gati E.; Koltai H.; Cannabis-derived compounds cannabichromene and \u03949-tetrahydrocannabinol interact and exhibit cytotoxic activity against urothelial cell carcinoma correlated with inhibition of cell migration and cytoskeleton organization. Molecules 2021,26(2),465","journal-title":"Molecules"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.3390\/ph13110328","volume":"13","author":"Raja A.","year":"2020","unstructured":"Raja A.; Ahmadi S.; de Costa F.; Li N.; Kerman K.; Attenuation of oxidative stress by cannabinoids and cannabis extracts in differentiated neuronal cells. Pharmaceuticals (Basel) 2020,13(11),E328","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41598-021-81049-2","volume":"11","author":"Anil S.M.","year":"2021","unstructured":"Anil S.M.; Shalev N.; Vinayaka A.C.; Nadarajan S.; Namdar D.; Belausov E.; Shoval I.; Mani K.A.; Mechrez G.; Koltai H.; Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep 2021,11(1),1462","journal-title":"Sci Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF02862859","volume":"28","author":"Li H-L.","year":"1973","unstructured":"Li H-L.; An archaeological and historical account of cannabis in China. Econ Bot 1973,28(4),437-448","journal-title":"Econ Bot"},{"key":"ref=18","first-page":"34","volume":"110","author":"Mikuriya T.H.","year":"1969","unstructured":"Mikuriya T.H.; Marijuana in medicine: Past, present and future. Calif Med 1969,110(1),34-40","journal-title":"Calif Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/02791072.1981.10471447","volume":"13","author":"Touw M.","year":"1981","unstructured":"Touw M.; The religious and medicinal uses of cannabis in China, India and Tibet. J Psychoactive Drugs 1981,13(1),23-34","journal-title":"J Psychoactive Drugs"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1155\/2001\/469629","volume":"6","author":"Kalant H.","year":"2001","unstructured":"Kalant H.; Medicinal use of cannabis: History and current status. Pain Res Manag 2001,6(2),80-91","journal-title":"Pain Res Manag"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1515\/9783110812060.293","author":"Pinho A.R.D.","year":"1975","unstructured":"Pinho A.R.D.; Social and medical aspects of the use of cannabis in Brazil. 1975,293-302"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/WNP.0000000000000644","volume":"37","author":"Carter A.","year":"2020","unstructured":"Carter A.; A north American history of cannabis use in the treatment of epilepsy. J Clin Neurophysiol 2020,37(1),35-38","journal-title":"J Clin Neurophysiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","volume":"78","author":"Elsohly M.A.","year":"2005","unstructured":"Elsohly M.A.; Slade D.; Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 2005,78(5),539-548","journal-title":"Life Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/molecules26092774","volume":"26","author":"Radwan M.M.","year":"2021","unstructured":"Radwan M.M.; Chandra S.; Gul S.; ElSohly M.A.; Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules 2021,26(9),2774","journal-title":"Molecules"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/np50008a001","volume":"43","author":"Turner C.E.","year":"1980","unstructured":"Turner C.E.; Elsohly M.A.; Boeren E.G.; Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 1980,43(2),169-234","journal-title":"J Nat Prod"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"104822","DOI":"10.1016\/j.phrs.2020.104822","volume":"157","author":"Alves P.","year":"2020","unstructured":"Alves P.; Amaral C.; Teixeira N.; Correia-da-Silva G.; Cannabis sativa: Much more beyond \u0394-tetrahydrocannabinol. Pharmacol Res 2020,157,104822","journal-title":"Pharmacol Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","volume":"33","author":"Hanu\u0161 L.O.","year":"2016","unstructured":"Hanu\u0161 L.O.; Meyer S.M.; Mu&#xF1;oz E.; Taglialatela-Scafati O.; Appendino G.; Phytocannabinoids: A unified critical inventory. Nat Prod Rep 2016,33(12),1357-1392","journal-title":"Nat Prod Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"Cristino L.","year":"2020","unstructured":"Cristino L.; Bisogno T.; Di Marzo V.; Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020,16(1),9-29","journal-title":"Nat Rev Neurol"},{"key":"ref=29","doi-asserted-by":"publisher","author":"Hazekamp A.","unstructured":"Hazekamp A.; Fischedick J.T.; D&#xED;ez M.L.; Lubbe A.; Ruhaak R.L.;  Chemistry of Cannabis. Elsevier, 2010; pp.\n1033-1084.","DOI":"10.1016\/B978-008045382-8.00091-5"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/08897077.2016.1219438","volume":"38","author":"Tournebize J.","year":"2017","unstructured":"Tournebize J.; Gibaja V.; Kahn J.P.; Acute effects of synthetic cannabinoids: Update 2015. Subst Abus 2017,38(3),344-366","journal-title":"Subst Abus"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1586\/17512433.2016.1167597","volume":"9","author":"Schifano F.","year":"2016","unstructured":"Schifano F.; Papanti G.D.; Orsolini L.; Corkery J.M.; Novel psychoactive substances: The pharmacology of stimulants and hallucinogens. Expert Rev Clin Pharmacol 2016,9(7),943-954","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.neuropharm.2015.08.041","volume":"99","author":"De Luca M.A.","year":"2015","unstructured":"De Luca M.A.; Bimpisidis Z.; Melis M.; Marti M.; Caboni P.; Valentini V.; Margiani G.; Pintori N.; Polis I.; Marsicano G.; Parsons L.H.; Di Chiara G.; Stimulation of in&#xA0;vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. Neuropharmacology 2015,99,705-714","journal-title":"Neuropharmacology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1503\/cmaj.130510","volume":"186","author":"Antoniou T.","year":"2014","unstructured":"Antoniou T.; Juurlink D.N.; Synthetic cannabinoids. CMAJ 2014,186(3),210","journal-title":"CMAJ"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MAJ.0000000000000466","volume":"350","author":"Mills B.","year":"2015","unstructured":"Mills B.; Yepes A.; Nugent K.; Synthetic cannabinoids. Am J Med Sci 2015,350(1),59-62","journal-title":"Am J Med Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.3390\/antibiotics9060297","volume":"9","author":"Klahn P.","year":"2020","unstructured":"Klahn P.; Cannabinoids-promising antimicrobial drugs or intoxicants with benefits? Antibiotics (Basel) 2020,9(6),E297","journal-title":"Antibiotics (Basel)"},{"key":"ref=36","first-page":"605","volume":"34","author":"Devane W.A.","year":"1988","unstructured":"Devane W.A.; Dysarz F.A.; Johnson M.R.; Melvin L.S.; Howlett A.C.; Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988,34(5),605-613","journal-title":"Mol Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"Matsuda L.A.","year":"1990","unstructured":"Matsuda L.A.; Lolait S.J.; Brownstein M.J.; Young A.C.; Bonner T.I.; Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990,346(6284),561-564","journal-title":"Nature"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"Munro S.","year":"1993","unstructured":"Munro S.; Thomas K.L.; Abu-Shaar M.; Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993,365(6441),61-65","journal-title":"Nature"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0367-326X(00)00171-4","volume":"71","author":"Nocerino E.","year":"2000","unstructured":"Nocerino E.; Amato M.; Izzo A.A.; Cannabis and cannabinoid receptors. Fitoterapia 2000,71(Suppl. 1),S6-S12","journal-title":"Fitoterapia"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"Pertwee R.G.","year":"2010","unstructured":"Pertwee R.G.; Howlett A.C.; Abood M.E.; Alexander S.P.; Di Marzo V.; Elphick M.R.; Greasley P.J.; Hansen H.S.; Kunos G.; Mackie K.; Mechoulam R.; Ross R.A.; International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB and CB. Pharmacol Rev 2010,62(4),588-631","journal-title":"Pharmacol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1874467212666190215112036","volume":"12","author":"Ye L.","year":"2019","unstructured":"Ye L.; Cao Z.; Wang W.; Zhou N.; New insights in cannabinoid receptor structure and signaling. Curr Mol Pharmacol 2019,12(3),239-248","journal-title":"Curr Mol Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fncel.2016.00294","volume":"10","author":"Kendall D.A.","year":"2017","unstructured":"Kendall D.A.; Yudowski G.A.; Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front Cell Neurosci 2017,10,294","journal-title":"Front Cell Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","volume":"176","author":"Krishna Kumar K.","year":"2019","unstructured":"Krishna Kumar K.; Shalev-Benami M.; Robertson M.J.; Hu H.; Banister S.D.; Hollingsworth S.A.; Latorraca N.R.; Kato H.E.; Hilger D.; Maeda S.; Weis W.I.; Farrens D.L.; Dror R.O.; Malhotra S.V.; Kobilka B.K.; Skiniotis G.; Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 2019,176(3),448-458.e12","journal-title":"Cell"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/bph.14625","volume":"176","author":"Spiller K.J.","year":"2019","unstructured":"Spiller K.J.; Bi G.H.; He Y.; Galaj E.; Gardner E.L.; Xi Z.X.; Cannabinoid CB and CB receptor mechanisms underlie cannabis reward and aversion in rats. Br J Pharmacol 2019,176(9),1268-1281","journal-title":"Br J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","volume":"20","author":"Mackie K.","year":"2008","unstructured":"Mackie K.; Cannabinoid receptors: Where they are and what they do. J Neuroendocrinol 2008,20(Suppl. 1),10-14","journal-title":"J Neuroendocrinol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","volume":"163","author":"Fern&#xE1;ndez-Ruiz J.","year":"2011","unstructured":"Fern&#xE1;ndez-Ruiz J.; Moreno-Martet M.; Rodr&#xED;guez-Cueto C.; Palomo-Garo C.; G&#xF3;mez-Ca&#xF1;as M.; Valdeolivas S.; Guaza C.; Romero J.; Guzm&#xE1;n M.; Mechoulam R.; Ramos J.A.; Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011,163(7),1365-1378","journal-title":"Br J Pharmacol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nm1561","volume":"13","author":"Maresz K.","year":"2007","unstructured":"Maresz K.; Pryce G.; Ponomarev E.D.; Marsicano G.; Croxford J.L.; Shriver L.P.; Ledent C.; Cheng X.; Carrier E.J.; Mann M.K.; Giovannoni G.; Pertwee R.G.; Yamamura T.; Buckley N.E.; Hillard C.J.; Lutz B.; Baker D.; Dittel B.N.; Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007,13(4),492-497","journal-title":"Nat Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","volume":"271","author":"McCaw E.A.","year":"2004","unstructured":"McCaw E.A.; Hu H.; Gomez G.T.; Hebb A.L.; Kelly M.E.; Denovan-Wright E.M.; Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington\u2019s disease transgenic mice. Eur J Biochem 2004,271(23-24),4909-4920","journal-title":"Eur J Biochem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"101301","DOI":"10.1016\/j.isci.2020.101301","volume":"23","author":"Shahbazi F.","year":"2020","unstructured":"Shahbazi F.; Grandi V.; Banerjee A.; Trant J.F.; Cannabinoids and cannabinoid receptors: The story so far. iScience 2020,23(7),101301","journal-title":"iScience"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"E5064","DOI":"10.3390\/ijms21145064","volume":"21","author":"An D.","year":"2020","unstructured":"An D.; Peigneur S.; Hendrickx L.A.; Tytgat J.; Targeting cannabinoid receptors: current status and prospects of natural products. Int J Mol Sci 2020,21(14),E5064","journal-title":"Int J Mol Sci"},{"key":"ref=51","author":"Khatoon E.","year":"2020","unstructured":"Khatoon E.; Banik K.; Harsha C.; Sailo B.L.; Thakur K.K.; Khwairakpam A.D.; Vikkurthi R.; Devi T.B.; Gupta S.C.; Kunnumakkara A.B.; Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. Semin Cancer Biol 2020","journal-title":"Semin Cancer Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3389\/fphar.2019.01614","volume":"10","author":"Choudhari A.S.","year":"2020","unstructured":"Choudhari A.S.; Mandave P.C.; Deshpande M.; Ranjekar P.; Prakash O.; Phytochemicals in cancer treatment: From preclinical dtudies to clinical practice. Front Pharmacol 2020,10,1614","journal-title":"Front Pharmacol"},{"key":"ref=53","first-page":"84","volume":"5","author":"Hosseini A.","year":"2015","unstructured":"Hosseini A.; Ghorbani A.; Cancer therapy with phytochemicals: Evidence from clinical studies. Avicenna J Phytomed 2015,5(2),84-97","journal-title":"Avicenna J Phytomed"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.semcancer.2020.04.006","volume":"68","author":"Kirtonia A.","year":"2021","unstructured":"Kirtonia A.; Gala K.; Fernandes S.G.; Pandya G.; Pandey A.K.; Sethi G.; Khattar E.; Garg M.; Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics. Semin Cancer Biol 2021,68,258-278","journal-title":"Semin Cancer Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"E1033","DOI":"10.3390\/cancers12041033","volume":"12","author":"Afrin F.","year":"2020","unstructured":"Afrin F.; Chi M.; Eamens A.L.; Duchatel R.J.; Douglas A.M.; Schneider J.; Gedye C.; Woldu A.S.; Dun M.D.; Can hemp help? low-thc cannabis and non-thc cannabinoids for the treatment of cancer. Cancers (Basel) 2020,12(4),E1033","journal-title":"Cancers (Basel)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejmech.2013.09.043","volume":"70","author":"Morales P.","year":"2013","unstructured":"Morales P.; Vara D.; Gom&#xE9;z-Ca&#xF1;as M.; Z&#xFA;&#xF1;iga M.C.; Olea-Azar C.; Goya P.; Fern&#xE1;ndez-Ruiz J.; D&#xED;az-Laviada I.; Jagerovic N.; Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Eur J Med Chem 2013,70,111-119","journal-title":"Eur J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/pros.23720","volume":"79","author":"Roberto D.","year":"2019","unstructured":"Roberto D.; Klotz L.H.; Venkateswaran V.; Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. Prostate 2019,79(2),151-159","journal-title":"Prostate"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.molonc.2014.12.010","volume":"9","author":"Elbaz M.","year":"2015","unstructured":"Elbaz M.; Nasser M.W.; Ravi J.; Wani N.A.; Ahirwar D.K.; Zhao H.; Oghumu S.; Satoskar A.R.; Shilo K.; Carson W.E.; Ganju R.K.; Modulation of the tumor microenvironment and inhibition of EGF\/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol 2015,9(4),906-919","journal-title":"Mol Oncol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"e0228909","DOI":"10.1371\/journal.pone.0228909","volume":"15","author":"Milian L.","year":"2020","unstructured":"Milian L.; Mata M.; Alcacer J.; Oliver M.; Sancho-Tello M.; Mart&#xED;n de Llano J.J.; Camps C.; Galbis J.; Carretero J.; Carda C.; Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS One 2020,15(2),e0228909","journal-title":"PLoS One"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.onc.1210641","volume":"27","author":"Preet A.","year":"2008","unstructured":"Preet A.; Ganju R.K.; Groopman J.E.; Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008,27(3),339-346","journal-title":"Oncogene"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1042\/bj3630183","volume":"363","author":"G&#xF3;mez del Pulgar T.","year":"2002","unstructured":"G&#xF3;mez del Pulgar T.; Velasco G.; S&#xE1;nchez C.; Haro A.; Guzm&#xE1;n M.; De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 2002,363(Pt 1),183-188","journal-title":"Biochem J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3747\/co.23.3080","volume":"23","author":"Velasco G.","year":"2016","unstructured":"Velasco G.; S&#xE1;nchez C.; Guzm&#xE1;n M.; Anticancer mechanisms of cannabinoids. Curr Oncol 2016,23(2),S23-S32","journal-title":"Curr Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.bjc.6603236","volume":"95","author":"Guzm&#xE1;n M.","year":"2006","unstructured":"Guzm&#xE1;n M.; Duarte M.J.; Bl&#xE1;zquez C.; Ravina J.; Rosa M.C.; Galve-Roperh I.; S&#xE1;nchez C.; Velasco G.; Gonz&#xE1;lez-Feria L.; A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006,95(2),197-203","journal-title":"Br J Cancer"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","volume":"26","author":"Turcott J.G.","year":"2018","unstructured":"Turcott J.G.; Del Roc&#xED;o Guillen N&#xFA;&#xF1;ez M.; Flores-Estrada D.; O&#xF1;ate-Oca&#xF1;a L.F.; Zatarain-Barr&#xF3;n Z.L.; Barr&#xF3;n F.; Arrieta O.; The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: A randomized, double-blind clinical trial. Support Care Cancer 2018,26(9),3029-3038","journal-title":"Support Care Cancer"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/082585979401000105","volume":"10","author":"Nelson K.","year":"1994","unstructured":"Nelson K.; Walsh D.; Deeter P.; Sheehan F.; A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994,10(1),14-18","journal-title":"J Palliat Care"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","volume":"22","author":"Brisbois T.D.","year":"2011","unstructured":"Brisbois T.D.; de Kock I.H.; Watanabe S.M.; Mirhosseini M.; Lamoureux D.C.; Chasen M.; MacDonald N.; Baracos V.E.; Wismer W.V.; Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011,22(9),2086-2093","journal-title":"Ann Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"Jatoi A.","year":"2002","unstructured":"Jatoi A.; Windschitl H.E.; Loprinzi C.L.; Sloan J.A.; Dakhil S.R.; Mailliard J.A.; Pundaleeka S.; Kardinal C.G.; Fitch T.R.; Krook J.E.; Novotny P.J.; Christensen B.; Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002,20(2),567-573","journal-title":"J Clin Oncol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"Johnson J.R.","year":"2010","unstructured":"Johnson J.R.; Burnell-Nugent M.; Lossignol D.; Ganae- Motan E.D.; Potts R.; Fallon M.T.; Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010,39(2),167-179","journal-title":"J Pain Symptom Manage"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jpainsymman.2012.07.014","volume":"46","author":"Johnson J.R.","year":"2013","unstructured":"Johnson J.R.; Lossignol D.; Burnell-Nugent M.; Fallon M.T.; An open-label extension study to investigate the long-term safety and tolerability of THC\/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 2013,46(2),207-218","journal-title":"J Pain Symptom Manage"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"Lichtman A.H.","year":"2018","unstructured":"Lichtman A.H.; Lux E.A.; McQuade R.; Rossetti S.; Sanchez R.; Sun W.; Wright S.; Kornyeyeva E.; Fallon M.T.; Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 2018,55(2),179-188.e1","journal-title":"J Pain Symptom Manage"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","volume":"47","author":"Lynch M.E.","year":"2014","unstructured":"Lynch M.E.; Cesar-Rittenberg P.; Hohmann A.G.; A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 2014,47(1),166-173","journal-title":"J Pain Symptom Manage"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"Kaplan G.G.","year":"2017","unstructured":"Kaplan G.G.; Ng S.C.; Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017,152(2),313-321.e2","journal-title":"Gastroenterology"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"Molodecky N.A.","year":"2012","unstructured":"Molodecky N.A.; Soon I.S.; Rabi D.M.; Ghali W.A.; Ferris M.; Chernoff G.; Benchimol E.I.; Panaccione R.; Ghosh S.; Barkema H.W.; Kaplan G.G.; Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012,142(1),46-54.e42","journal-title":"Gastroenterology"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"471","DOI":"10.7326\/0003-4819-76-3-112-6-471_1","volume":"112","author":"Baron J.A.","year":"1990","unstructured":"Baron J.A.; Folan R.D.; Kelley M.L.; Ulcerative colitis and marijuana. Ann Intern Med 1990,112(6),471","journal-title":"Ann Intern Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","volume":"87","author":"Herkenham M.","year":"1990","unstructured":"Herkenham M.; Lynn A.B.; Little M.D.; Johnson M.R.; Melvin L.S.; de Costa B.R.; Rice K.C.; Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990,87(5),1932-1936","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000358155","volume":"32","author":"Naftali T.","year":"2014","unstructured":"Naftali T.; Mechulam R.; Lev L.B.; Konikoff F.M.; Cannabis for inflammatory bowel disease. Dig Dis 2014,32(4),468-474","journal-title":"Dig Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/ibd\/izy319","volume":"25","author":"Swaminath A.","year":"2019","unstructured":"Swaminath A.; Berlin E.P.; Cheifetz A.; Hoffenberg E.; Kinnucan J.; Wingate L.; Buchanan S.; Zmeter N.; Rubin D.T.; The role of cannabis in the management of inflammatory bowel disease: A review of clinical, scientific, and regulatory information. Inflamm Bowel Dis 2019,25(3),427-435","journal-title":"Inflamm Bowel Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/ecco-jcc\/jjaa253","volume":"15","author":"Becker W.","year":"2021","unstructured":"Becker W.; Alrafas H.R.; Busbee P.B.; Walla M.D.; Wilson K.; Miranda K.; Cai G.; Putluri V.; Putluri N.; Nagarkatti M.; Nagarkatti P.S.; Cannabinoid receptor activation on haematopoietic cells and enterocytes protects against colitis. J Crohn\u2019s Colitis 2021,15(6),1032-1048","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.gastro.2005.05.026","volume":"129","author":"Wright K.","year":"2005","unstructured":"Wright K.; Rooney N.; Feeney M.; Tate J.; Robertson D.; Welham M.; Ward S.; Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing. Gastroenterology 2005,129(2),437-453","journal-title":"Gastroenterology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.taap.2011.11.005","volume":"258","author":"Singh U.P.","year":"2012","unstructured":"Singh U.P.; Singh N.P.; Singh B.; Price R.L.; Nagarkatti M.; Nagarkatti P.S.; Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-\/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 2012,258(2),256-267","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.22516\/25007440.407","volume":"35","author":"Casta&#xF1;eda Cardona C.","year":"2020","unstructured":"Casta&#xF1;eda Cardona C.; Lasalvia P.; Ferreriros A.; Pantoja Ruiz C.; Restrepo Jimenez P.; Rosselli D.; Cannabis in inflammatory bowel disease: A narrative summary. Rev Colomb Gastroenterol 2020,35(1),104-113","journal-title":"Rev Colomb Gastroenterol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MEG.0000000000000779","volume":"29","author":"Goyal H.","year":"2017","unstructured":"Goyal H.; Singla U.; Gupta U.; May E.; Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol 2017,29(2),135-143","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1157\/13097468","volume":"128","author":"Garc&#xED;a-Planella E.","year":"2007","unstructured":"Garc&#xED;a-Planella E.; Mar&#xED;n L.; Dom&#xE8;nech E.; Bernal I.; Ma&#xF1;osa M.; Zabana Y.; Gassull M.A.; Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease. Med Clin (Barc) 2007,128(2),45-48","journal-title":"Med Clin (Barc)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1097\/01.MIB.0000435851.94391.37","volume":"19","author":"Ravikoff Allegretti J.","year":"2013","unstructured":"Ravikoff Allegretti J.; Courtwright A.; Lucci M.; Korzenik J.R.; Levine J.; Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013,19(13),2809-2814","journal-title":"Inflamm Bowel Dis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/01.MIB.0000440982.79036.d6","volume":"20","author":"Storr M.","year":"2014","unstructured":"Storr M.; Devlin S.; Kaplan G.G.; Panaccione R.; Andrews C.N.; Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn\u2019s disease. Inflamm Bowel Dis 2014,20(3),472-480","journal-title":"Inflamm Bowel Dis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/MEG.0b013e328349bb4c","volume":"23","author":"Lal S.","year":"2011","unstructured":"Lal S.; Prasad N.; Ryan M.; Tangri S.; Silverberg M.S.; Gordon A.; Steinhart H.; Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011,23(10),891-896","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MPG.0000000000001474","volume":"64","author":"Phatak U.P.","year":"2017","unstructured":"Phatak U.P.; Rojas-Velasquez D.; Porto A.; Pashankar D.S.; Prevalence and patterns of marijuana use in young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2017,64(2),261-264","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jpeds.2018.03.041","volume":"199","author":"Hoffenberg E.J.","year":"2018","unstructured":"Hoffenberg E.J.; McWilliams S.K.; Mikulich-Gilbertson S.K.; Murphy B.V.; Lagueux M.; Robbins K.; Hoffenberg A.S.; de Zoeten E.; Hopfer C.J.; Marijuana use by adolescents and young adults with inflammatory bowel disease. J Pediatr 2018,199,99-105","journal-title":"J Pediatr"},{"key":"ref=89","first-page":"455","volume":"13","author":"Naftali T.","year":"2011","unstructured":"Naftali T.; Lev L.B.; Yablecovitch D.; Half E.; Konikoff F.M.; Treatment of Crohn\u2019s disease with cannabis: An observational study. Isr Med Assoc J 2011,13(8),455-458","journal-title":"Isr Med Assoc J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000332079","volume":"85","author":"Lahat A.","year":"2012","unstructured":"Lahat A.; Lang A.; Ben-Horin S.; Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study. Digestion 2012,85(1),1-8","journal-title":"Digestion"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","volume":"62","author":"Naftali T.","year":"2017","unstructured":"Naftali T.; Mechulam R.; Marii A.; Gabay G.; Stein A.; Bronshtain M.; Laish I.; Benjaminov F.; Konikoff F.M.; Low-dose cannabidiol is safe but not effective in the treatment for Crohn\u2019s disease, a randomized controlled trial. Dig Dis Sci 2017,62(6),1615-1620","journal-title":"Dig Dis Sci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cgh.2013.04.034","volume":"11","author":"Naftali T.","year":"2013","unstructured":"Naftali T.; Bar-Lev Schleider L.; Dotan I.; Lansky E.P.; Sklerovsky Benjaminov F.; Konikoff F.M.; Cannabis induces a clinical response in patients with Crohn\u2019s disease: A prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013,11(10),1276-1280.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.drugalcdep.2015.08.035","volume":"156","author":"Weiss A.","year":"2015","unstructured":"Weiss A.; Friedenberg F.; Patterns of cannabis use in patients with inflammatory bowel disease: A population based analysis. Drug Alcohol Depend 2015,156,84-89","journal-title":"Drug Alcohol Depend"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/MIB.0b013e31827f27c8","volume":"19","author":"Koning M.","year":"2013","unstructured":"Koning M.; Ailabouni R.; Gearry R.B.; Frampton C.M.; Barclay M.L.; Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study. Inflamm Bowel Dis 2013,19(4),767-778","journal-title":"Inflamm Bowel Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","volume":"9","author":"Vu&#x10D;kovi\u0107 S.","year":"2018","unstructured":"Vu&#x10D;kovi\u0107 S.; Srebro D.; Vujovi\u0107 K.S.; Vu&#x10D;eti\u0107 &#x10C;.; Prostran M.; Cannabinoids and pain: New insights from old molecules. Front Pharmacol 2018,9,1259","journal-title":"Front Pharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"42639","DOI":"10.1074\/jbc.M107351200","volume":"276","author":"Huang S.M.","year":"2001","unstructured":"Huang S.M.; Bisogno T.; Petros T.J.; Chang S.Y.; Zavitsanos P.A.; Zipkin R.E.; Sivakumar R.; Coop A.; Maeda D.Y.; De Petrocellis L.; Burstein S.; Di Marzo V.; Walker J.M.; Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 2001,276(46),42639-42644","journal-title":"J Biol Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"Russo E.B.","year":"2005","unstructured":"Russo E.B.; Burnett A.; Hall B.; Parker K.K.; Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005,30(8),1037-1043","journal-title":"Neurochem Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pain.2008.04.006","volume":"139","author":"Staton P.C.","year":"2008","unstructured":"Staton P.C.; Hatcher J.P.; Walker D.J.; Morrison A.D.; Shapland E.M.; Hughes J.P.; Chong E.; Mander P.K.; Green P.J.; Billinton A.; Fulleylove M.; Lancaster H.C.; Smith J.C.; Bailey L.T.; Wise A.; Brown A.J.; Richardson J.C.; Chessell I.P.; The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008,139(1),225-236","journal-title":"Pain"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.pbb.2014.07.008","volume":"124","author":"Grim T.W.","year":"2014","unstructured":"Grim T.W.; Ghosh S.; Hsu K.L.; Cravatt B.F.; Kinsey S.G.; Lichtman A.H.; Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol Biochem Behav 2014,124,405-411","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","volume":"182","author":"Ware M.A.","year":"2010","unstructured":"Ware M.A.; Wang T.; Shapiro S.; Robinson A.; Ducruet T.; Huynh T.; Gamsa A.; Bennett G.J.; Collet J.P.; Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ 2010,182(14),E694-E701","journal-title":"CMAJ"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","volume":"133","author":"Nurmikko T.J.","year":"2007","unstructured":"Nurmikko T.J.; Serpell M.G.; Hoggart B.; Toomey P.J.; Morlion B.J.; Haines D.; Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007,133(1-3),210-220","journal-title":"Pain"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","volume":"260","author":"Langford R.M.","year":"2013","unstructured":"Langford R.M.; Mares J.; Novotna A.; Vachova M.; Novakova I.; Notcutt W.; Ratcliffe S.; A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013,260(4),984-997","journal-title":"J Neurol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","volume":"18","author":"Serpell M.","year":"2014","unstructured":"Serpell M.; Ratcliffe S.; Hovorka J.; Schofield M.; Taylor L.; Lauder H.; Ehler E.; A double-blind, randomized, placebo-controlled, parallel group study of THC\/CBD spray in peripheral neuropathic pain treatment. Eur J Pain 2014,18(7),999-1012","journal-title":"Eur J Pain"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","volume":"14","author":"Wilsey B.","year":"2013","unstructured":"Wilsey B.; Marcotte T.; Deutsch R.; Gouaux B.; Sakai S.; Donaghe H.; Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013,14(2),136-148","journal-title":"J Pain"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"van de Donk T.","year":"2019","unstructured":"van de Donk T.; Niesters M.; Kowal M.A.; Olofsen E.; Dahan A.; van Velzen M.; An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 2019,160(4),860-869","journal-title":"Pain"},{"key":"ref=106","first-page":"e102","volume":"169","author":"Poli P.","year":"2018","unstructured":"Poli P.; Crestani F.; Salvadori C.; Valenti I.; Sannino C.; Medical cannabis in patients with chronic pain: effect on pain relief, pain disability, and psychological aspects. A prospective non randomized single arm clinical trial. Clin Ter 2018,169(3),e102-e107","journal-title":"Clin Ter"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"E2669","DOI":"10.3390\/molecules25112669","volume":"25","author":"Nyakudya T.T.","year":"2020","unstructured":"Nyakudya T.T.; Tshabalala T.; Dangarembizi R.; Erlwanger K.H.; Ndhlala A.R.; The potential therapeutic value of medicinal plants in the management of metabolic disorders. Molecules 2020,25(11),E2669","journal-title":"Molecules"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.3390\/plants6040042","volume":"6","author":"Altemimi A.","year":"2017","unstructured":"Altemimi A.; Lakhssassi N.; Baharlouei A.; Watson D.G.; Lightfoot D.A.; Phytochemicals: Extraction, isolation, and identification of bioactive compounds from plant extracts. Plants 2017,6(4),E42","journal-title":"Plants"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/10408398.2012.755149","volume":"56","author":"Rodriguez-Casado A.","year":"2016","unstructured":"Rodriguez-Casado A.; The health potential of fruits and vegetables phytochemicals: Notable examples. Crit Rev Food Sci Nutr 2016,56(7),1097-1107","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fendo.2020.00114","volume":"11","author":"Bielawiec P.","year":"2020","unstructured":"Bielawiec P.; Harasim-Symbor E.; Chabowski A.; Phytocannabinoids: Useful drugs for the treatment of obesity? special focus on cannabidiol. Front Endocrinol (Lausanne) 2020,11,114","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11892-019-1248-9","volume":"19","author":"Veilleux A.","year":"2019","unstructured":"Veilleux A.; Di Marzo V.; Silvestri C.; The expanded endocannabinoid system\/endocannabinoidome as a potential target for treating diabetes mellitus. Curr Diab Rep 2019,19(11),117","journal-title":"Curr Diab Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00125-007-0890-y","volume":"51","author":"Berm&#xFA;dez-Silva F.J.","year":"2008","unstructured":"Berm&#xFA;dez-Silva F.J.; Su&#xE1;rez J.; Baixeras E.; Cobo N.; Bautista D.; Cuesta-Mu&#xF1;oz A.L.; Fuentes E.; Juan-Pico P.; Castro M.J.; Milman G.; Mechoulam R.; Nadal A.; Rodr&#xED;guez de Fonseca F.; Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008,51(3),476-487","journal-title":"Diabetologia"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4161\/isl.2.5.12729","volume":"2","author":"Li C.","year":"2010","unstructured":"Li C.; Bowe J.E.; Jones P.M.; Persaud S.J.; Expression and function of cannabinoid receptors in mouse islets. Islets 2010,2(5),293-302","journal-title":"Islets"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.regpep.2010.04.013","volume":"163","author":"Vilches-Flores A.","year":"2010","unstructured":"Vilches-Flores A.; Delgado-Buenrostro N.L.; Navarrete-V&#xE1;zquez G.; Villalobos-Molina R.; CB1 cannabinoid receptor expression is regulated by glucose and feeding in rat pancreatic islets. Regul Pept 2010,163(1-3),81-87","journal-title":"Regul Pept"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00109-009-0459-y","volume":"87","author":"Scherer T.","year":"2009","unstructured":"Scherer T.; Buettner C.; The dysregulation of the endocannabinoid system in diabesity-a tricky problem. J Mol Med (Berl) 2009,87(7),663-668","journal-title":"J Mol Med (Berl)"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1474651410385860","volume":"10","author":"Frisher M.","year":"2010","unstructured":"Frisher M.; White S.; Varbiro G.; Voisey C.; Perumal D.; Crome I.; Khideja N.; Bashford J.; The role of cannabis and cannabinoids in diabetes. Br J Diabetes Vasc Dis 2010,10(6),267-273","journal-title":"Br J Diabetes Vasc Dis"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1567-5769(01)00003-0","volume":"1","author":"Li X.","year":"2001","unstructured":"Li X.; Kaminski N.E.; Fischer L.J.; Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol 2001,1(4),699-712","journal-title":"Int Immunopharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajpath.2011.11.003","volume":"180","author":"Horv&#xE1;th B.","year":"2012","unstructured":"Horv&#xE1;th B.; Mukhopadhyay P.; Hask&#xF3; G.; Pacher P.; The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 2012,180(2),432-442","journal-title":"Am J Pathol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2337\/dc16-0650","volume":"39","author":"Jadoon K.A.","year":"2016","unstructured":"Jadoon K.A.; Ratcliffe S.H.; Barrett D.A.; Thomas E.L.; Stott C.; Bell J.D.; O\u2019Sullivan S.E.; Tan G.D.; Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 2016,39(10),1777-1786","journal-title":"Diabetes Care"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00415-014-7502-9","volume":"262","author":"Hoggart B.","year":"2015","unstructured":"Hoggart B.; Ratcliffe S.; Ehler E.; Simpson K.H.; Hovorka J.; Lej&#x10D;ko J.; Taylor L.; Lauder H.; Serpell M.; A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC\/CBD oromucosal spray in the management of neuropathic pain. J Neurol 2015,262(1),27-40","journal-title":"J Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","volume":"16","author":"Wallace M.S.","year":"2015","unstructured":"Wallace M.S.; Marcotte T.D.; Umlauf A.; Gouaux B.; Atkinson J.H.; Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain 2015,16(7),616-627","journal-title":"J Pain"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"Xu D.H.","year":"2020","unstructured":"Xu D.H.; Cullen B.D.; Tang M.; Fang Y.; The Effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol 2020,21(5),390-402","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","volume":"153","author":"Toth C.","year":"2012","unstructured":"Toth C.; Mawani S.; Brady S.; Chan C.; Liu C.; Mehina E.; Garven A.; Bestard J.; Korngut L.; An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012,153(10),2073-2082","journal-title":"Pain"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/bjp.2008.130","volume":"154","author":"Solinas M.","year":"2008","unstructured":"Solinas M.; Goldberg S.R.; Piomelli D.; The endocannabinoid system in brain reward processes. Br J Pharmacol 2008,154(2),369-383","journal-title":"Br J Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"Scheen A.J.","year":"2006","unstructured":"Scheen A.J.; Finer N.; Hollander P.; Jensen M.D.; Van Gaal L.F.; Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006,368(9548),1660-1672","journal-title":"Lancet"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"Christensen R.","year":"2007","unstructured":"Christensen R.; Kristensen P.K.; Bartels E.M.; Bliddal H.; Astrup A.; Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007,370(9600),1706-1713","journal-title":"Lancet"},{"key":"ref=127","first-page":"pyu094","volume":"18","author":"Tudge L.","year":"2014","unstructured":"Tudge L.; Williams C.; Cowen P.J.; McCabe C.; Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol 2014,18(6),pyu094","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/archneurol.2007.56","volume":"65","author":"Soto C.","year":"2008","unstructured":"Soto C.; Estrada L.D.; Protein misfolding and neurodegeneration. Arch Neurol 2008,65(2),184-189","journal-title":"Arch Neurol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1146\/annurev.pathmechdis.2.010506.092044","volume":"3","author":"Yankner B.A.","year":"2008","unstructured":"Yankner B.A.; Lu T.; Loerch P.; The aging brain. Annu Rev Pathol 2008,3,41-66","journal-title":"Annu Rev Pathol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","volume":"15","author":"Iuvone T.","year":"2009","unstructured":"Iuvone T.; Esposito G.; De Filippis D.; Scuderi C.; Steardo L.; Cannabidiol: A promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009,15(1),65-75","journal-title":"CNS Neurosci Ther"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1196\/annals.1403.002","volume":"1122","author":"Skaper S.D.","year":"2007","unstructured":"Skaper S.D.; The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 2007,1122,23-34","journal-title":"Ann N Y Acad Sci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","volume":"30","author":"Zuardi A.W.","year":"2008","unstructured":"Zuardi A.W.; Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008,30(3),271-280","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"393","DOI":"10.14740\/jocmr4159","volume":"12","author":"Oberbarnscheidt T.","year":"2020","unstructured":"Oberbarnscheidt T.; Miller N.S.; The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res 2020,12(7),393-403","journal-title":"J Clin Med Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"Pertwee R.G.","year":"2008","unstructured":"Pertwee R.G.; The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008,153(2),199-215","journal-title":"Br J Pharmacol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/mds.20111","volume":"19","author":"Venderov&#xE1; K.","year":"2004","unstructured":"Venderov&#xE1; K.; R&#x16F;zicka E.; Vor&#xED;sek V.; Visnovsk&#xFD; P.; Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 2004,19(9),1102-1106","journal-title":"Mov Disord"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"Castillo P.E.","year":"2012","unstructured":"Castillo P.E.; Younts T.J.; Ch&#xE1;vez A.E.; Hashimotodani Y.; Endocannabinoid signaling and synaptic function. Neuron 2012,76(1),70-81","journal-title":"Neuron"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.26142","volume":"30","author":"Kluger B.","year":"2015","unstructured":"Kluger B.; Triolo P.; Jones W.; Jankovic J.; The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015,30(3),313-327","journal-title":"Mov Disord"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","volume":"20","author":"Bilsland L.G.","year":"2006","unstructured":"Bilsland L.G.; Dick J.R.; Pryce G.; Petrosino S.; Di Marzo V.; Baker D.; Greensmith L.; Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006,20(7),1003-1005","journal-title":"FASEB J"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","volume":"101","author":"Shoemaker J.L.","year":"2007","unstructured":"Shoemaker J.L.; Seely K.A.; Reed R.L.; Crow J.P.; Prather P.L.; The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007,101(1),87-98","journal-title":"J Neurochem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"Trapp B.D.","year":"2008","unstructured":"Trapp B.D.; Nave K.A.; Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci 2008,31,247-269","journal-title":"Annu Rev Neurosci"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"Izzo A.A.","year":"2009","unstructured":"Izzo A.A.; Borrelli F.; Capasso R.; Di Marzo V.; Mechoulam R.; Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009,30(10),515-527","journal-title":"Trends Pharmacol Sci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.freeradbiomed.2011.01.007","volume":"51","author":"Booz G.W.","year":"2011","unstructured":"Booz G.W.; Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011,51(5),1054-1061","journal-title":"Free Radic Biol Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fphar.2020.00124","volume":"11","author":"Cassano T.","year":"2020","unstructured":"Cassano T.; Villani R.; Pace L.; Carbone A.; Bukke V.N.; Orkisz S.; Avolio C.; Serviddio G.; From cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol 2020,11,124","journal-title":"Front Pharmacol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"e00682","DOI":"10.1002\/prp2.682","volume":"8","author":"de Almeida D.L.","year":"2020","unstructured":"de Almeida D.L.; Devi L.A.; Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 2020,8(6),e00682","journal-title":"Pharmacol Res Perspect"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jnc.14098","volume":"142","author":"Basavarajappa B.S.","year":"2017","unstructured":"Basavarajappa B.S.; Shivakumar M.; Joshi V.; Subbanna S.; Endocannabinoid system in neurodegenerative disorders. J Neurochem 2017,142(5),624-648","journal-title":"J Neurochem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","volume":"75","author":"Fern&#xE1;ndez-Ruiz J.","year":"2013","unstructured":"Fern&#xE1;ndez-Ruiz J.; Sagredo O.; Pazos M.R.; Garc&#xED;a C.; Pertwee R.; Mechoulam R.; Mart&#xED;nez-Orgado J.; Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013,75(2),323-333","journal-title":"Br J Clin Pharmacol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","volume":"18","author":"Riva N.","year":"2019","unstructured":"Riva N.; Mora G.; Sorar&#xF9; G.; Lunetta C.; Ferraro O.E.; Falzone Y.; Leocani L.; Fazio R.; Comola M.; Comi G.; Group C.S.; Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): A multicentre, double-blind, randomised, placebo- controlled, phase 2 trial. Lancet Neurol 2019,18(2),155-164","journal-title":"Lancet Neurol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1352458506072514","volume":"12","author":"Bowling A.","year":"2006","unstructured":"Bowling A.; Cannabinoids in MS-are we any closer to knowing how best to use them? Mult Scler 2006,12(5),523-525","journal-title":"Mult Scler"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fneur.2017.00299","volume":"8","author":"Rudroff T.","year":"2017","unstructured":"Rudroff T.; Honce J.M.; Cannabis and multiple sclerosis-the way forward. Front Neurol 2017,8,299","journal-title":"Front Neurol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/1352458506070947","volume":"12","author":"Chong M.S.","year":"2006","unstructured":"Chong M.S.; Wolff K.; Wise K.; Tanton C.; Winstock A.; Silber E.; Cannabis use in patients with multiple sclerosis. Mult Scler 2006,12(5),646-651","journal-title":"Mult Scler"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"Vaney C.","year":"2004","unstructured":"Vaney C.; Heinzel-Gutenbrunner M.; Jobin P.; Tschopp F.; Gattlen B.; Hagen U.; Schnelle M.; Reif M.; Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004,10(4),417-424","journal-title":"Mult Scler"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"Wade D.T.","year":"2004","unstructured":"Wade D.T.; Makela P.; Robson P.; House H.; Bateman C.; Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004,10(4),434-441","journal-title":"Mult Scler"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","volume":"65","author":"Rog D.J.","year":"2005","unstructured":"Rog D.J.; Nurmikko T.J.; Friede T.; Young C.A.; Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005,65(6),812-819","journal-title":"Neurology"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","volume":"14","author":"Collin C.","year":"2007","unstructured":"Collin C.; Davies P.; Mutiboko I.K.; Ratcliffe S.; Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007,14(3),290-296","journal-title":"Eur J Neurol"},{"key":"ref=155","first-page":"1","author":"Perras C.","year":"2005","unstructured":"Perras C.; Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005(72),1-4","journal-title":"Issues Emerg Health Technol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"Novotna A.","year":"2011","unstructured":"Novotna A.; Mares J.; Ratcliffe S.; Novakova I.; Vachova M.; Zapletalova O.; Gasperini C.; Pozzilli C.; Cefaro L.; Comi G.; Rossi P.; Ambler Z.; Stelmasiak Z.; Erdmann A.; Montalban X.; Klimek A.; Davies P.; Sativex Spasticity Study, G., A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(R)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011,18(9),1122-1131","journal-title":"Eur J Neurol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1352458511419700","volume":"18","author":"Notcutt W.","year":"2012","unstructured":"Notcutt W.; Langford R.; Davies P.; Ratcliffe S.; Potts R.; A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler 2012,18(2),219-228","journal-title":"Mult Scler"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"Collin C.","year":"2010","unstructured":"Collin C.; Ehler E.; Waberzinek G.; Alsindi Z.; Davies P.; Powell K.; Notcutt W.; O\u2019Leary C.; Ratcliffe S.; Nov&#xE1;kov&#xE1; I.; Zapletalova O.; Pikov&#xE1; J.; Ambler Z.; A double-blind, randomized, placebo-controlled, parallel- group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010,32(5),451-459","journal-title":"Neurol Res"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1177\/1352458510378020","volume":"16","author":"Kavia R.B.","year":"2010","unstructured":"Kavia R.B.; De Ridder D.; Constantinescu C.S.; Stott C.G.; Fowler C.J.; Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010,16(11),1349-1359","journal-title":"Mult Scler"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/physrev.00019.2008","volume":"89","author":"Kano M.","year":"2009","unstructured":"Kano M.; Ohno-Shosaku T.; Hashimotodani Y.; Uchigashima M.; Watanabe M.; Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009,89(1),309-380","journal-title":"Physiol Rev"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"Marsicano G.","year":"2003","unstructured":"Marsicano G.; Goodenough S.; Monory K.; Hermann H.; Eder M.; Cannich A.; Azad S.C.; Cascio M.G.; Guti&#xE9;rrez S.O.; van der Stelt M.; L&#xF3;pez-Rodriguez M.L.; Casanova E.; Sch&#xFC;tz G.; Zieglg&#xE4;nsberger W.; Di Marzo V.; Behl C.; Lutz B.; CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003,302(5642),84-88","journal-title":"Science"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"L&#xF3;pez-Send&#xF3;n Moreno J.L.","year":"2016","unstructured":"L&#xF3;pez-Send&#xF3;n Moreno J.L.; Garc&#xED;a Caldentey J.; Trigo Cubillo P.; Ruiz Romero C.; Garc&#xED;a Ribas G.; Alonso Arias M.A.; Garc&#xED;a de Y&#xE9;benes M.J.; Tol&#xF3;n R.M.; Galve-Roperh I.; Sagredo O.; Valdeolivas S.; Resel E.; Ortega-Gutierrez S.; Garc&#xED;a-Bermejo M.L.; Fern&#xE1;ndez Ruiz J.; Guzm&#xE1;n M.; Garc&#xED;a de Y&#xE9;benes Prous J.; A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 2016,263(7),1390-1400","journal-title":"J Neurol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"Consroe P.","year":"1991","unstructured":"Consroe P.; Laguna J.; Allender J.; Snider S.; Stern L.; Sandyk R.; Kennedy K.; Schram K.; Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 1991,40(3),701-708","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","volume":"40","author":"Balash Y.","year":"2017","unstructured":"Balash Y.; Bar-Lev Schleider L.; Korczyn A.D.; Shabtai H.; Knaani J.; Rosenberg A.; Baruch Y.; Djaldetti R.; Giladi N.; Gurevich T.; Medical cannabis in parkinson disease: Real-life patients\u2019 experience. Clin Neuropharmacol 2017,40(6),268-272","journal-title":"Clin Neuropharmacol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","volume":"37","author":"Lotan I.","year":"2014","unstructured":"Lotan I.; Treves T.A.; Roditi Y.; Djaldetti R.; Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study. Clin Neuropharmacol 2014,37(2),41-44","journal-title":"Clin Neuropharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"Sieradzan K.A.","year":"2001","unstructured":"Sieradzan K.A.; Fox S.H.; Hill M.; Dick J.P.; Crossman A.R.; Brotchie J.M.; Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: A pilot study. Neurology 2001,57(11),2108-2111","journal-title":"Neurology"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.2174\/13816128113199990620","volume":"20","author":"Karila L.","year":"2014","unstructured":"Karila L.; Roux P.; Rolland B.; Benyamina A.; Reynaud M.; Aubin H.J.; Lan&#xE7;on C.; Acute and long-term effects of cannabis use: A review. Curr Pharm Des 2014,20(25),4112-4118","journal-title":"Curr Pharm Des"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"Bergamaschi M.M.","year":"2011","unstructured":"Bergamaschi M.M.; Queiroz R.H.; Zuardi A.W.; Crippa J.A.; Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011,6(4),237-249","journal-title":"Curr Drug Saf"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"640222","DOI":"10.3389\/fpsyt.2021.640222","volume":"12","author":"Crocker C.E.","year":"2021","unstructured":"Crocker C.E.; Carter A.J.E.; Emsley J.G.; Magee K.; Atkinson P.; Tibbo P.G.; When cannabis use goes wrong: Mental health side effects of cannabis use that present to emergency services. Front Psychiatry 2021,12,640222","journal-title":"Front Psychiatry"},{"key":"ref=170","author":"Hall W.","year":"2018","unstructured":"Hall W.;  European Monitoring centre for drugs and drug addiction 2018","journal-title":"European Monitoring centre for drugs and drug addiction"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220525124818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205247\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220525124818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:53:11Z","timestamp":1693669991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205247\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220525124818","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}